Founded in 2002, Prollenium Medical Technologies was born from the determination of a talented group of individuals specialized in their respective fields. Since then, the company has developed a stream of cutting edge products in tissue reconstruction.

Prollenium focuses its attention on the research, marketing and sales of novel biomaterials that can be used in a wide array of tissue reconstruction applications. These indications include but are not limited to the areas of urology, dermatology, osteoarthritis and podiatry.

In 2009 the company invested heavily in the only high speed automated syringe manufacturing and packaging line for solutions and viscous gels in Canada. This new facility located just north of Toronto Canada in Aurora houses the company’s sales, marketing, R&D and manufacturing staff and services its global sales chain. Capacity at this new site exceeds over 2 million syringes per year.

Prollenium exports to over 80 countries in the world, and is currently working on further approvals for new products for the global market.